Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a dose-finding study for the investigational product Lancovutide (Moli1901) in the
exploratory phase IIb to establish minimum effective dose, optimal dose, and maximum safe
dose. Additionally, the tolerability of Moli1901 shall be investigated.